Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Genetic polymorphisms of matrix metalloproteinases 1-3 and their inhibitor are not associated with premature labor.

Lathouras K, Saso S, Tzafetas M, Kalinderi K, Fidani S, Zournatzi V, Kyrgiou M, Fotopoulou C, Ghaem-Maghami S, Tzafetas I.

Future Sci OA. 2018 Aug 24;4(9):FSO332. doi: 10.4155/fsoa-2018-0047. eCollection 2018 Oct.

2.

What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2018 Oct 29. doi: 10.1007/s00404-018-4945-8. [Epub ahead of print] No abstract available.

PMID:
30374648
3.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv259. doi: 10.1093/annonc/mdy157. No abstract available.

PMID:
30285216
4.

Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients.

Cunnea P, Gorgy T, Petkos K, Gowers SAN, Lu H, Morera C, Wu W, Lawton P, Nixon K, Leong CL, Sorbi F, Domenici L, Paterson A, Curry E, Gabra H, Boutelle MG, Drakakis EM, Fotopoulou C.

Sci Rep. 2018 Oct 2;8(1):14695. doi: 10.1038/s41598-018-32720-8.

5.

Impact of right upper quadrant cytoreductive techniques with extensive liver mobilization on postoperative hepatic function and risk of liver failure in patients with advanced ovarian cancer.

Nasser S, Lathouras K, Nixon K, Campbell J, Stocks G, Jiao L, Fotopoulou C.

Gynecol Oncol. 2018 Sep 29. pii: S0090-8258(18)31247-2. doi: 10.1016/j.ygyno.2018.09.028. [Epub ahead of print]

PMID:
30278996
6.

Is there a role for HIPEC in ovarian cancer?

Harter P, du Bois A, Sehouli J, Mahner S, Vergote I, Chiva L, Gonzalez-Martin A, Fotopoulou C.

Arch Gynecol Obstet. 2018 Nov;298(5):859-860. doi: 10.1007/s00404-018-4908-0.

PMID:
30232581
7.

Copy number signatures and mutational processes in ovarian carcinoma.

Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD.

Nat Genet. 2018 Sep;50(9):1262-1270. doi: 10.1038/s41588-018-0179-8. Epub 2018 Aug 13.

PMID:
30104763
8.

The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Antony J, Zanini E, Kelly Z, Tan TZ, Karali E, Alomary M, Jung Y, Nixon K, Cunnea P, Fotopoulou C, Paterson A, Roy-Nawathe S, Mills GB, Huang RY, Thiery JP, Gabra H, Recchi C.

EMBO Rep. 2018 Aug;19(8). pii: e45670. doi: 10.15252/embr.201745670. Epub 2018 Jun 15.

PMID:
29907679
9.

HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?

Fotopoulou C, Sehouli J, Mahner S, Harter P, Van Nieuwenhuysen E, Gonzalez-Martin A, Vergote I, Chiva L, Du Bois A.

Ann Oncol. 2018 Aug 1;29(8):1610-1613. doi: 10.1093/annonc/mdy198. No abstract available.

PMID:
29873689
10.

Fertility-sparing Surgery for Presumed Early-stage Invasive Cervical Cancer: A Survey of Practice in the United Kingdom.

Tzafetas M, Mitra A, Kalliala I, Lever S, Fotopoulou C, Farthing A, Smith JR, Martin-Hirsch P, Paraskevaidis E, Kyrgiou M.

Anticancer Res. 2018 Jun;38(6):3641-3646. doi: 10.21873/anticanres.12639.

PMID:
29848721
11.

Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Fotopoulou C, Frilling A, Herzog T, Moderau N, Tabassum N, Krell J, Stebbing J.

Oncotarget. 2018 Mar 13;9(19):15164. doi: 10.18632/oncotarget.24689. eCollection 2018 Mar 13.

12.

Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Fotopoulou C, Frilling A, Herzog T, Moderau N, Tabassum N, Krell J, Stebbing J.

Oncotarget. 2017 Dec 27;9(5):6007-6014. doi: 10.18632/oncotarget.23675. eCollection 2018 Jan 19. Erratum in: Oncotarget. 2018 Mar 13;9(19):15164.

13.

High temporal resolution delayed analysis of clinical microdialysate streams.

Gowers SAN, Hamaoui K, Cunnea P, Anastasova S, Curto VF, Vadgama P, Yang GZ, Papalois V, Drakakis EM, Fotopoulou C, Weber SG, Boutelle MG.

Analyst. 2018 Jan 29;143(3):715-724. doi: 10.1039/c7an01209h.

14.

Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.

Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; RARECARENet Working Group.

Eur J Surg Oncol. 2017 Nov 3. pii: S0748-7983(17)30947-2. doi: 10.1016/j.ejso.2017.09.025. [Epub ahead of print]

PMID:
29108961
15.

A Review of Thoracic and Mediastinal Cytoreductive Techniques in Advanced Ovarian Cancer: Extending the Boundaries.

Nasser S, Kyrgiou M, Krell J, Haidopoulos D, Bristow R, Fotopoulou C.

Ann Surg Oncol. 2017 Nov;24(12):3700-3705. doi: 10.1245/s10434-017-6051-8. Epub 2017 Aug 31. Review.

PMID:
28861808
16.

The passive biomechanics of human pelvic collecting lymphatic vessels.

Athanasiou D, Edgar LT, Jafarnejad M, Nixon K, Duarte D, Hawkins ED, Jamalian S, Cunnea P, Lo Celso C, Kobayashi S, Fotopoulou C, Moore JE Jr.

PLoS One. 2017 Aug 21;12(8):e0183222. doi: 10.1371/journal.pone.0183222. eCollection 2017.

17.

Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.

Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM.

J Surg Oncol. 2018 Feb;117(2):236-244. doi: 10.1002/jso.24801. Epub 2017 Aug 8.

18.

Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study.

Minig L, Heitz F, Cibula D, Bakkum-Gamez JN, Germanova A, Dowdy SC, Kalogera E, Zapardiel I, Lindemann K, Harter P, Scambia G, Petrillo M, Zorrero C, Zanagnolo V, Rebollo JMC, du Bois A, Fotopoulou C.

Ann Surg Oncol. 2017 Sep;24(9):2720-2726. doi: 10.1245/s10434-017-5919-y. Epub 2017 Jun 12.

PMID:
28608122
19.

British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.

Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, Kehoe S, Ledermann J, Morrison J, Naik R, Rolland P, Sundar S.

Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:123-139. doi: 10.1016/j.ejogrb.2017.04.016. Epub 2017 Apr 18. No abstract available.

20.

BGCS uterine cancer guidelines: Recommendations for practice.

Sundar S, Balega J, Crosbie E, Drake A, Edmondson R, Fotopoulou C, Gallos I, Ganesan R, Gupta J, Johnson N, Kitson S, Mackintosh M, Martin-Hirsch P, Miles T, Rafii S, Reed N, Rolland P, Singh K, Sivalingam V, Walther A.

Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:71-97. doi: 10.1016/j.ejogrb.2017.04.015. Epub 2017 Apr 13. Review.

PMID:
28437632
21.

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA.

Br J Cancer. 2017 May 9;116(10):1294-1301. doi: 10.1038/bjc.2017.86. Epub 2017 Mar 30.

22.

Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.

Phelps DL, Borley JV, Flower KJ, Dina R, Darb-Esfahani S, Braicu I, Sehouli J, Fotopoulou C, Wilhelm-Benartzi CS, Gabra H, Yazbek J, Chatterjee J, Ip J, Khan H, Likos-Corbett MT, Brown R, Ghaem-Maghami S.

Br J Cancer. 2017 May 9;116(10):1287-1293. doi: 10.1038/bjc.2017.83. Epub 2017 Mar 28.

23.

Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival-A Case Series.

Domenici L, Nixon K, Sorbi F, Kyrgiou M, Yazbek J, Hall M, Campbell J, Gibbons N, Park WE, Gabra H, Fotopoulou C.

Int J Gynecol Cancer. 2017 May;27(4):759-767. doi: 10.1097/IGC.0000000000000936.

24.

Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.

Kyrgiou M, Kalliala IE, Mitra A, Fotopoulou C, Ghaem-Maghami S, Martin-Hirsch PP, Cruickshank M, Arbyn M, Paraskevaidis E.

Cochrane Database Syst Rev. 2017 Jan 26;1:CD009836. doi: 10.1002/14651858.CD009836.pub2. Review.

25.

Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.

Fotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D, Chiva L, Gabra H, Colombo N, du Bois A.

J Clin Oncol. 2017 Feb 20;35(6):587-590. doi: 10.1200/JCO.2016.71.0723. Epub 2017 Jan 9. No abstract available.

26.

Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer.

Cunnea P, Gowers S, Moore JE Jr, Drakakis E, Boutelle M, Fotopoulou C.

Converg Sci Phys Oncol. 2017;3. pii: 013002. doi: 10.1088/2057-1739/aa5cf1. Epub 2017 Feb 23.

27.

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.

Alifrangis C, Thornton A, Fotopoulou C, Krell J, Gabra H.

Gynecol Oncol Rep. 2016 Nov 6;18:42-44. eCollection 2016 Nov.

28.

Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.

Nasser S, Lazaridis A, Evangelou M, Jones B, Nixon K, Kyrgiou M, Gabra H, Rockall A, Fotopoulou C.

Gynecol Oncol. 2016 Nov;143(2):264-269. doi: 10.1016/j.ygyno.2016.08.322. Epub 2016 Aug 29.

PMID:
27586894
29.

European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery.

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A.

Int J Gynecol Cancer. 2016 Sep;26(7):1354-63. doi: 10.1097/IGC.0000000000000767.

PMID:
27648648
30.

Immediate referral to colposcopy versus cytological surveillance for low-grade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta-analysis of the literature.

Kyrgiou M, Kalliala I, Mitra A, Ng KY, Raglan O, Fotopoulou C, Martin-Hirsch P, Paraskevaidis E, Arbyn M.

Int J Cancer. 2017 Jan 1;140(1):216-223. doi: 10.1002/ijc.30419. Epub 2016 Oct 12. Review.

31.

Cervical intraepithelial neoplasia: screening and management.

Mitra A, Tzafetas M, Lyons D, Fotopoulou C, Paraskevaidis E, Kyrgiou M.

Br J Hosp Med (Lond). 2016 Aug 2;77(8):C118-23. doi: 10.12968/hmed.2016.77.8.C118. Review. No abstract available.

PMID:
27487071
32.

Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914].

du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S.

Eur J Cancer. 2016 Sep;65:192-193. doi: 10.1016/j.ejca.2016.06.014. Epub 2016 Jul 25. No abstract available.

PMID:
27468640
33.

Incidence of Lymph Node Metastases in Apparent Early-Stage Low-Grade Epithelial Ovarian Cancer: A Comprehensive Review.

Lago V, Minig L, Fotopoulou C.

Int J Gynecol Cancer. 2016 Oct;26(8):1407-14. doi: 10.1097/IGC.0000000000000787. Review.

34.

Erratum to: The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.

Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J.

Arch Gynecol Obstet. 2016 Jun;293(6):1367. No abstract available.

PMID:
27075494
35.

Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities.

Fotopoulou C, Jones BP, Savvatis K, Campbell J, Kyrgiou M, Farthing A, Brett S, Roux R, Hall M, Rustin G, Gabra H, Jiao L, Stümpfle R.

Arch Gynecol Obstet. 2016 Sep;294(3):607-14. doi: 10.1007/s00404-016-4080-3. Epub 2016 Apr 4.

36.

Neuroendocrine Neoplasms of the Ovary: A Retrospective Study of the North Eastern German Society of Gynecologic Oncology (NOGGO).

Sehouli J, Woopen H, Pavel M, Richter R, Lauterbach LK, Taube E, Darb-Esfahani S, Fotopoulou C, Pietzner K.

Anticancer Res. 2016 Mar;36(3):1003-9.

PMID:
26976990
37.

The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.

Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J.

Arch Gynecol Obstet. 2016 Apr;293(4):695-700. doi: 10.1007/s00404-016-4035-8. Epub 2016 Feb 19. Erratum in: Arch Gynecol Obstet. 2016 Jun;293(6):1367.

PMID:
26894303
38.

Limitations to the use of carboplatin-based therapy in advanced ovarian cancer.

Fotopoulou C.

EJC Suppl. 2014 Dec;12(2):13-6. doi: 10.1016/S1359-6349(15)70005-4. Epub 2015 Jan 13.

39.

A method for voltage measurements of cancerous vs non-cancerous omentum.

Wu W, Vitharana K, Gorgy T, Paterson A, Cunnea P, Gabra H, Fotopoulou C, Boutelle MG, Drakakis EM.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:7514-7. doi: 10.1109/EMBC.2015.7320130.

PMID:
26738030
40.

Hemodynamic Consequences of Malignant Ascites in Epithelial Ovarian Cancer Surgery*: A Prospective Substudy of a Randomized Controlled Trial.

Hunsicker O, Fotopoulou C, Pietzner K, Koch M, Krannich A, Sehouli J, Spies C, Feldheiser A.

Medicine (Baltimore). 2015 Dec;94(49):e2108. doi: 10.1097/MD.0000000000002108.

41.

The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids.

Kessler M, Hoffmann K, Brinkmann V, Thieck O, Jackisch S, Toelle B, Berger H, Mollenkopf HJ, Mangler M, Sehouli J, Fotopoulou C, Meyer TF.

Nat Commun. 2015 Dec 8;6:8989. doi: 10.1038/ncomms9989.

42.

Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer.

Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J; Kommission Ovar of the AGO.

Geburtshilfe Frauenheilkd. 2015 Oct;75(10):1021-1027.

43.

Patient Support Groups Identifying Clinical Equipoise in UK Gynaecological Oncology Surgeons as the Basis for Trials in Ultraradical Surgery for Advanced Ovarian Cancer.

Naik R, Bayne L, Founta C, Kehoe S, Rustin G, Fotopoulou C.

Int J Gynecol Cancer. 2016 Jan;26(1):91-4. doi: 10.1097/IGC.0000000000000565.

PMID:
26512783
44.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

45.

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Roman LD, Gabra H, Fotopoulou C, Sood AK.

Eur J Cancer. 2015 Sep;51(14):1978-88. doi: 10.1016/j.ejca.2015.07.012. Epub 2015 Jul 31.

46.

The next steps in improving the outcomes of advanced ovarian cancer.

Openshaw MR, Fotopoulou C, Blagden S, Gabra H.

Womens Health (Lond). 2015 Jun;11(3):355-67. doi: 10.2217/whe.15.6. Review.

47.

Should Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO Ovar.

Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J; Kommission Ovar of the Gynecologic Oncology Study Group (AGO).

Geburtshilfe Frauenheilkd. 2015 Apr;75(4):339-341. No abstract available.

48.

Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer.

Fotopoulou C, El-Balat A, du Bois A, Sehouli J, Harter P, Muallem MZ, Krätschell RW, Traut A, Heitz F.

Arch Gynecol Obstet. 2015 Dec;292(6):1321-7. doi: 10.1007/s00404-015-3746-6. Epub 2015 May 20.

PMID:
25990476
49.

The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.

Fotopoulou C, Sehouli J, Ewald-Riegler N, de Gregorio N, Reuss A, Richter R, Mahner S, Kommoss F, Schmalfeldt B, Fehm T, Hanker L, Wimberger P, Canzler U, Pfisterer J, Kommoss S, Hauptmann S, du Bois A; ROBOT investigators.

Int J Gynecol Cancer. 2015 Sep;25(7):1248-52. doi: 10.1097/IGC.0000000000000476.

PMID:
25978292
50.

Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO.

Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J.

Arch Gynecol Obstet. 2015 Jul;292(1):231-4. doi: 10.1007/s00404-015-3697-y. Epub 2015 Apr 26. Review.

PMID:
25914073

Supplemental Content

Loading ...
Support Center